吴学雨;胡楠;张竞舟;洪义东;卞保祥;宋子琰;吴风雷;

• 1:徐州医科大学附属连云港医院

摘要(Abstract)：

翻译后修饰是指多肽或蛋白质在翻译后所经历的共同加工过程，近年研究发现，程序性细胞死亡蛋白配体1(PD-L1)的翻译后存在多种修饰形式，例如糖基化、泛素化、磷酸化、甲基化、棕榈酰化和乙酰化等。翻译后修饰可通过影响PD-L1的蛋白质稳定性，促进PD-L1介导的肿瘤免疫逃逸，阻断PD-L1与程序性细胞死亡蛋白1(PD-1)的结合，增强自身免疫细胞对肿瘤细胞的杀伤功能，在PD-L1蛋白稳定性、易位和蛋白—蛋白相互作用中发挥重要作用，翻译后修饰的异常改变直接影响PD-L1介导的免疫抵抗。鉴于翻译后修饰机制通常是药物抑制肿瘤的治疗靶点，靶向PD-L1翻译后修饰可能是一种增强抗肿瘤免疫反应的新策略。

关键词(KeyWords)： 程序性细胞死亡蛋白配体;翻译后修饰;糖基化修饰;泛素化修饰;磷酸化修饰;甲基化修饰;棕榈酰化修饰;乙酰化修饰

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金青年科学基金资助项目（81802347）;; 吴阶平医学基金资助项目（320.675.19058）

作者(Authors): 吴学雨;胡楠;张竞舟;洪义东;卞保祥;宋子琰;吴风雷;

参考文献(References)：

• [1]梁文焰，马爱霞.PD-1/PD-L1抑制剂治疗血液恶性肿瘤综述[J].中国医院药学杂志，2019,39(23):2445-2449.
• [2]LOPEZ-SAMBROOKS C,SHRIMAL S,KHODIER C,et al.Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells[J].Nat Chem Biol,2016,12(12):1023-1030.
• [3]LI C W,LIM S O,CHUNG E M,et al.Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1[J].Cancer Cell,2018,33(2):187-201.
• [4]LI C W,LIM S O,XIA W,et al.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity[J].Nat Commun,2016,7:12632.
• [5]LIAO C,AN J,TAN Z,et al.Changes in protein glycosylation in head and neck squamous cell carcinoma[J].J Cancer,2021,12(5):1455-1466.
• [6]RUAN Z,LIANG M,LAI M,et al.KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the beta-catenin/STT3 signaling pathway[J].Int Immunopharmacol,2020,78:106003.
• [7]HSU J M,XIA W,HSU Y H,et al.STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion[J].Nat Commun,2018,9(1):1908.
• [8]SHAO B,LI C W,LIM S O,et al.Deglycosylation of PD-L1 by2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer[J].Am J Cancer Res,2018,8(9):1837-1846.
• [9]KIM B,SUN R,OH W,et al.Saccharide analog,2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation[J].Mol Carcinog,2020,59(7):691-700.
• [10]VERDURA S C E,CORTADA E,BRUNET J,et al.Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity6[J].Aging(Albany NY),2020,12(1):8-34.
• [11]CHA J H,YANG W H,XIA W,et al.Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1[J].Mol Cell,2018,71(4):606-620.
• [12]CHAN L C,LI C W,XIA W,et al.IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion[J].J Clin Invest,2019,129(8):3324-3338.
• [13]王梦媛，裴晏梓，谭理.PD-L1基因表达的调控机制[J].生命的化学，2020,40(10):1683-1692.
• [14]HORITA H,LAW A,HONG S,et al.Identifying regulatory posttranslational modifications of PD-L1:a focus on monoubiquitinaton[J].Neoplasia,2017,19(4):346-353.
• [15]NOLAND C L,GIERKE S,SCHNIER P D,et al.Palmitoylation of TEAD transcription factors is required for their stability and function in hippo pathway signaling[J].Structure,2016,24(1):179-186.
• [16]YANG Y,HSU J M,SUN L,et al.Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J].Cell Res,2019,29(1):83-86.
• [17]YAO H,LAN J,LI C,et al.Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours[J].Nat Biomed Eng,2019,3(4):306-317.
• [18]ALI A,LEVANTINI E,TEO J T,et al.Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer[J].EMBO Mol Med,2018,10(3):e8313.
• [19]SHAHID M,KIM M,JIN P,et al.S-palmitoylation as a functional regulator of proteins associated with cisplatin resistance in bladder cancer[J].Int J Biol Sci,2020,16(14):2490-2505.
• [20]ELASHI A A,SASIDHARAN NAIR V,TAHA R Z,et al.DNAmethylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients[J].Oncoimmunology,2019,8(2):e1542918.
• [21]GOLTZ D G H,DIETRICH J,SCHROECK F,et al.PDCD1(PD-1)promoter methylation predicts outcome in head and neck squamous cell carcinoma patients[J].Oncotarget,2017,8(25):41011-41020.
• [22]FRANZEN A,VOGT T J,MüLLER T.PD-L1(CD274)and PD-L2 (PDCD1LG2) promoter methylation is associatedwith HPV infection and transcriptional repression in head and neck squamous cell carcinomas[J].Oncotarget,2017,9(1):641-650.
• [23]GEVENSLEBEN H H E,GOLTZ D,DIETRICH J,et al.PD-L1promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy[J].Oncotarget,2016,7(48):79943-79955.
• [24]HESHAM H M,LASHEEN D S,ABOUZID K A M.Chimeric HDAC inhibitors:comprehensive review on the HDAC-based strategies developed to combat cancer[J].Med Res Rev,2018,38(6):2058-2109.
• [25]HU G,HE N,CAI C,et al.HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer[J].Pancreatology,2019,19(2):383-389.
• [26]SHI Y,FU Y,ZHANG X,et al.Romidepsin(FK228)regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer[J].Cancer Immunol Immunother,2021,70(1):61-73.